Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Warning Letter Hits Strides On Data Integrity

Was blue binder of batch records in scrap yard a sign of deeper problems?

Executive Summary

Even after the US FDA warns Strides on uncontrolled records destruction and poor OOS investigations at its Puducherry plant, firm remains confident in its US market growth projections.

You may also be interested in...



US Supply Chain "Elasticity" Pilot Would Get Major Funds In House-Passed Legislation

COMPETES Act also includes enhanced penalties for drug makers who falsify or destroy records, power for the FDA to recall harmful drugs, funding for drug manufacturing technology and additional supply chain flexibility efforts.

New Strides CEO Puts Emphasis On Execution

Strides' newly-appointed CEO, R Ananthanarayanan, sees no reason to change course as the firm's current strategy continues to yield positive results. The company posted a 29% increase in third-quarter revenues on the back of 62% growth in the US.

Strides' New CEO Reiterates Strategy, Thrust On Execution

Newly-appointed CEO at Strides, R Ananthanarayanan, sees no reason to change course as current strategy continues yielding positive results. Company posts 29% increase in third-quarter revenues on the back of 62% growth in the US

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS140515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel